The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

ISSN: 2212-4039 (Online)
ISSN: 1872-2113 (Print)


Volume 8, 3 Issues, 2014


Download PDF Flyer




Recent Patents on Drug Delivery & Formulation

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Mark A. Babizhayev
Innovative Vision Products, Inc
County of New Castle, Delaware
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

Author(s): Irina Kadiyala and Dylan Jacobs

Affiliation: Vertex Pharmaceuticals Incorporated, Department of Formulation Development, 130 Waverly St., Cambridge, MA 02139-4242.

Abstract

This patent review focuses exclusively on the oral delivery of mesalamine (5-ASA) and excludes oral mesalamine pro-drug and rectal delivery formulations. The formulation strategies of marketed formulations (Apriso®, Asacol®, Lialda® and Pentasa®) and non-marketed formulations are reviewed and explained by decoding formulation specifics that enable the site specific delivery for the treatment of inflammatory bowel disease.

Keywords: Apriso, asacol, asacol HD, 5-ASA, Crohn’s disease and ulcerative colitis, inflammatory bowel disease, lialda, mesalamine, oral delivery, pentasa.

Download Free Rights and Permissions

  
  



Article Details

Volume: 8
Issue Number: 1
First Page: 3
Last Page: 11
Page Count: 9
DOI: 10.2174/18722113113079990014
Advertisement

Related Journals



Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science